Exelixis (EXEL) Stock Rating Upgraded by TheStreet

Share on StockTwits

Exelixis (NASDAQ:EXEL) was upgraded by investment analysts at TheStreet from a “c+” rating to a “b-” rating in a report issued on Monday.

EXEL has been the subject of several other reports. Oppenheimer set a $40.00 price objective on shares of Exelixis and gave the stock a “buy” rating in a research report on Thursday, November 1st. Goldman Sachs Group began coverage on shares of Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 price target on the stock. BidaskClub upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 30th. ValuEngine upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 1st. Finally, Guggenheim began coverage on shares of Exelixis in a research note on Monday, September 17th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis currently has an average rating of “Buy” and a consensus target price of $29.44.

Exelixis stock opened at $20.18 on Monday. The firm has a market cap of $6.23 billion, a PE ratio of 39.57, a PEG ratio of 1.24 and a beta of 2.34. Exelixis has a 12-month low of $13.42 and a 12-month high of $32.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.54.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.22. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $174.14 million. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The company’s revenue for the quarter was up 47.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.26 EPS. As a group, sell-side analysts forecast that Exelixis will post 1.3 earnings per share for the current year.

In related news, CMO Gisela Schwab sold 12,000 shares of Exelixis stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $14.16, for a total transaction of $169,920.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Christopher J. Senner sold 8,791 shares of Exelixis stock in a transaction on Friday, November 30th. The stock was sold at an average price of $19.70, for a total transaction of $173,182.70. The disclosure for this sale can be found here. Insiders have sold a total of 289,367 shares of company stock worth $5,219,346 over the last quarter. 4.80% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in EXEL. Raymond James Financial Services Advisors Inc. increased its stake in Exelixis by 16.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 20,599 shares of the biotechnology company’s stock valued at $443,000 after purchasing an additional 2,948 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Exelixis by 17.1% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 23,496 shares of the biotechnology company’s stock valued at $416,000 after purchasing an additional 3,428 shares during the period. Meeder Asset Management Inc. increased its stake in Exelixis by 21.2% in the third quarter. Meeder Asset Management Inc. now owns 23,504 shares of the biotechnology company’s stock valued at $416,000 after purchasing an additional 4,117 shares during the period. Principal Financial Group Inc. increased its stake in Exelixis by 5.1% in the first quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock valued at $2,016,000 after purchasing an additional 4,445 shares during the period. Finally, Louisiana State Employees Retirement System increased its stake in Exelixis by 6.8% in the third quarter. Louisiana State Employees Retirement System now owns 81,600 shares of the biotechnology company’s stock valued at $1,446,000 after purchasing an additional 5,200 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: Book Value Per Share – BVPS

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply